For the quarter ending 2025-09-30, OPK had $143,479K increase in cash & cash equivalents over the period. -$37,782K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 21,631 | -216,054 |
| Depreciation and amortization | 22,740 | 46,514 |
| Non-cash interest | 2,309 | 61,557 |
| Amortization of deferred financing costs | 138 | 4,959 |
| Losses from investments in investees | -3 | -9 |
| Equity-based compensation employees and non-employees | 2,969 | 4,828 |
| Impairment of intangible assets | 1,007 | - |
| Realized gain on disposal of fixed assets and sales of equity securities | -12 | 3,858 |
| Change in fair value of equity securities and derivative instruments | 287 | -1,734 |
| Inducement expense and loss on debt conversion | 0 | 32,647 |
| Deferred income tax (benefit) provision | 18,287 | -23,137 |
| Gain on sale of assets | 101,576 | - |
| Accounts receivable, net | -4,389 | -19,115 |
| Inventory, net | -624 | 5,915 |
| Other current assets and prepaid expenses | -1,035 | 2,318 |
| Other assets | -412 | 510 |
| Accounts payable | -5,244 | 8,087 |
| Foreign currency measurement | -2,676 | -1,989 |
| Accrued expenses and other liabilities | -420 | -43,643 |
| Net cash used in operating activities | -34,647 | -117,974 |
| Investments in investees | 7,665 | - |
| Proceeds from sale of equity securities | 0 | 51,655 |
| Purchase of marketable securities | 0 | - |
| Proceeds from the sale of property, plant and equipment | 13 | 181 |
| Capital expenditures | 3,135 | 6,477 |
| Investments in investees | - | 7,665 |
| Proceeds from labcorp sales including escrow released | 197,770 | - |
| Net cash provided by investing activities | 194,648 | 37,694 |
| Issuance of 3.00 convertible senior notes, net (including related parties) | 0 | 0 |
| Issuance of 2044 notes | 0 | - |
| Debt issuance costs | 0 | 0 |
| Share repurchase | 15,278 | 18,255 |
| Proceeds from the exercise of common stock options | 0 | -123 |
| Repurchase of 2029 convertible notes | 62,208 | - |
| Borrowings on lines of credit | 7,869 | 16,636 |
| Repayments of lines of credit | 8,797 | 19,387 |
| Settlement of convertible notes | -62,208 | 62,382 |
| Net cash (provided by) used in financing activities | -16,206 | -83,511 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -316 | 3,571 |
| Net decrease (increase) in cash, cash equivalents and restricted cash | 143,479 | -160,220 |
| Cash and cash equivalents at beginning of period | 445,615 | - |
| Cash and cash equivalents at end of period | 428,874 | - |
OPKO HEALTH, INC. (OPK)
OPKO HEALTH, INC. (OPK)